A three-year-old male Labrador retriever was presented at the Clinic of Internal Medicine, University of Zagreb, Croatia. The owner reported that the dog was ataxic, and this was evident by its markedly unsteady, swaying gait. The dog also had difficulty rising and fell several times while trying to stand. It had come into contact with the explosive, pentaerythrityl tetranitrate, while training to detect explosives. The following clinical symptoms were observed: bradycardia, depression, mild disorientation and a broad-based stance. The dog had conscious proprioceptive deficits in the hindlimbs, but cranial nerve function was normal except for miosis. Ion scan analysis of the dog's serum after evaporation of the current phase by mass spectroscopy revealed the presence of fragments that are characteristic of pentaerythrityl tetranitrate. The aim of the present case report was to identify pentaerythrityl tetranitrate poisoning and describe the clinical signs of pentaerythrityl tetranitrate poisoning in dogs. To the authors' knowledge, there are no published scientific articles on pentaerythrityl tetranitrate poisoning in dogs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1748-5827.2008.00549.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cardiovascular health of women 10 to 20 years after placenta-related pregnancy diseases considering the possible effect of pentaerythrityl tetranitrate treatment during pregnancy on long-term maternal cardiovascular health (PAVA study).
PLoS One
October 2024
Department of Obstetrics, University Hospital, Friedrich Schiller University, Jena, Germany.
Background: Women developing preeclampsia (PE) or fetal growth restriction (FGR) during pregnancy are at higher risk for cardiovascular diseases (CVD) later in life. We aimed to analyse cardiovascular health of women 10-20 years after affected pregnancies in comparison to women after uneventful pregnancies. In addition, we assessed a potential long-term effect of the NO-donor pentaerythrityl tetranitrate (PETN).
View Article and Find Full Text PDFGestational age at birth, birth weight, and gestational age when intrauterine brain sparing occurs determines the neonatal outcome in growth-restricted infants born before 32 weeks of gestation: a retrospective cohort analysis.
Front Pediatr
July 2024
Department of Obstetrics, University Hospital Jena, Jena, Germany.
Background: Preterm birth and fetal growth restriction are the main determinants of perinatal mortality. In the absence of therapeutic interventions, management is restricted to the observation of fetal growth and fetoplacental perfusion to determine the timing of delivery. Fetal circulatory redistribution, known as "brain sparing," represents a sign of fetal hypoxia and has been implemented in algorithms for when to deliver.
View Article and Find Full Text PDFPentaerythrityl tetranitrate improves the outcome of children born to mothers with compromised uterine perfusion-12-months follow-up and safety data of the double-blind randomized PETN trial.
Am J Obstet Gynecol MFM
April 2024
Department of Obstetrics, Jena University Hospital (Prof. Groten and Prof. Schleußner), Jena, Germany.
Background: This is a follow-up study to the pentaerythrityl tetranitrate randomized controlled multicenter trial that reports neonatal outcome data of newborns admitted to neonatal intensive care units and outcome data of the offspring at 12 months of age.
Objective: We present data on adverse events reported during the study to document the safety of pentaerythrityl tetranitrate treatment during pregnancy. To further evaluate the effects of pentaerythrityl tetranitrate on neonatal and long-term outcomes, we present follow up data from of 240 children at 12 months of age, including information on height, weight, head circumference, developmental milestones, and the presence of chronic disease and of 144 newborns admitted to the neonatal intensive care unit during the trial.
A liquid chromatographic-mass spectrometric procedure for analysis of pentaerythrityl tetranitrate metabolites - Development, validation and application to ovine serum and human plasma samples.
J Chromatogr B Analyt Technol Biomed Life Sci
February 2024
Jena University Hospital, Department of Obstetrics, Friedrich Schiller University Jena, Germany.
Pentaerythrityl tetranitrate (PETN) is an established drug in the treatment of coronary heart disease and heart failure. It is assumed, that the vasodilative and vasoprotective effects of PETN also have a positive impact on pregnant patients with impaired placental perfusion and studies evaluating the effect of PETN in risk pregnancies have been carried out. In the context of these clinical trials, measuring of serum levels of PETN and its metabolites pentaerythrityl trinitrate (PETriN), pentaerythrityl dinitrate (PEDN), pentaerythrityl mononitrate (PEMN) and pentaerythritol (PE) were required.
View Article and Find Full Text PDFResults, meta-analysis and a first evaluation of UR, the urinary nitrate-to-nitrite molar ratio, as a measure of nitrite reabsorption in experimental and clinical settings.
Amino Acids
July 2018
Institute of Clinical Biochemistry, Hannover Medical School, Hannover, Germany.
We recently found that renal carbonic anhydrase (CA) is involved in the reabsorption of inorganic nitrite (NO), an abundant reservoir of nitric oxide (NO) in tissues and cells. Impaired NO synthesis in the endothelium and decreased NO bioavailability in the circulation are considered major contributors to the development and progression of renal and cardiovascular diseases in different conditions including diabetes. Isolated human and bovine erythrocytic CAII and CAIV can convert nitrite to nitrous acid (HONO) and its anhydride NO which, in the presence of thiols (RSH), are further converted to S-nitrosothiols (RSNO) and NO.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!